BLACK DIAMOND THERAPEUTICS I (BDTX)

Company Profile

Black Diamond Therapeutics, Inc. is a precision oncology medicine company, which engages in discovery and development of small molecule, masterkey therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 54 full-time employees. The company went IPO on 2020-01-30. The Company’s MasterKey therapies are designed to address broad genetically defined patient populations, overcome resistance, minimize wild-type mediated toxicities, and be brain penetrant to treat central nervous system (CNS) disease. The firm is advancing two clinical-stage programs: BDTX-1535, a brain-penetrant fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor targeting EGFR mutant non-small cell lung cancer (NSCLC) and glioblastoma (GBM), and BDTX-4933, a brain-penetrant RAF MasterKey inhibitor targeting KRAS, NRAS and BRAF alterations in solid tumors. Its BDTX-4876 is a MasterKey inhibitor of oncogenic FGFR2/3 mutations with selectivity versus FGFR1/4. The firm is also focused on a development candidate against an undisclosed, validated oncogene.

Company Info

BLACK DIAMOND THERAPEUTICS I

One Main Street, 14th Floor

Cambridge MASSACHUSETTS 02142

P: 16174175868

CEO: David M. Epstein

Employees: 54

Website: https://www.blackdiamondtherapeutics.com/